Skip to main content
. 2021 Jun 6;22(2):841. doi: 10.3892/etm.2021.10273

Figure 4.

Figure 4

GSK126 decreases atherosclerosis development by downregulating LOX-1 and VCAM1 expression levels in plaques. (A) Representative photomicrographs of LOX-1 and VCAM1 expression in lesions following anti-LOX-1 and anti-VCAM1 antibody staining. Magnification, x40. (B) Quantitative analysis of LOX-1 expression area in the lesions (n=5). (C) Quantitative analysis of VCAM1 expression area in the lesions (n=5). Results are presented as the mean ± SD. ***P≤0.001. HFD, High fat diet; VCAM1, vascular cell adhesion molecule 1; LOX-1, oxidized low-density lipoprotein receptor 1.